Zobrazeno 1 - 10
of 89
pro vyhledávání: '"NVA237"'
Autor:
Arievich Helen, Overend Tim, Renard Didier, Gibbs Michael, Alagappan Vijay, Looby Michael, Banerji Donald
Publikováno v:
BMC Pulmonary Medicine, Vol 12, Iss 1, p 74 (2012)
Abstract Background Glycopyrronium bromide (NVA237) is an inhaled long-acting muscarinic antagonist in development for treatment of COPD. This study compared the efficacy and safety of once-daily (OD) and twice-daily (BID) glycopyrronium bromide regi
Externí odkaz:
https://doaj.org/article/163dbfc29a7949779d44770da4d6b972
Autor:
D'Urzo Anthony, Ferguson Gary T, van Noord Jan A, Hirata Kazuto, Martin Carmen, Horton Rachael, Lu Yimeng, Banerji Donald, Overend Tim
Publikováno v:
Respiratory Research, Vol 12, Iss 1, p 156 (2011)
Abstract Background NVA237 is a once-daily dry-powder formulation of the long-acting muscarinic antagonist glycopyrronium bromide in development for the treatment of chronic obstructive pulmonary disease (COPD). The glycopyrronium bromide in COPD air
Externí odkaz:
https://doaj.org/article/362ba4aa2720476aa6bef758655ace84
A case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use
Publikováno v:
BMC Research Notes
Background Glycopyrronium bromide has recently been approved as a once daily maintenance inhalation therapy for moderate to severe chronic obstructive pulmonary disease (COPD). Efficacy and safety trial data have found rare cases of significant QT pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8867bdb98dde5dc7c8b49d12f415ab06
https://doi.org/10.1186/s13104-016-2105-4
https://doi.org/10.1186/s13104-016-2105-4
Autor:
Y Lu, Donald Banerji, Tim Overend, C Martin, Edward Kerwin, Vijay Alagappan, Jacques Hébert, Nicola Gallagher
Publikováno v:
The European Respiratory Journal
NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD). The GLycopyrronium bromide in COPD airWays clinical Study 2 (GLOW2) evaluated the efficacy and s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb7a10fd804f8369c6bd3f1bb6aabeee
http://europepmc.org/articles/PMC3485572
http://europepmc.org/articles/PMC3485572
Publikováno v:
Respiratory Medicine. 105(3):337-342
NVA237 is a novel, once daily inhaled long-acting muscarinic antagonist administered via a dry powder inhaler. This study aimed to assess the 24-h bronchodilatory effect following 14 days of treatment with inhaled NVA237 in patients with mild, modera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e27b774c3532d62b89b1d0835776635f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Kai M Beeh,1 Dave Singh,2 Lilla Di Scala,3 Anton Drollmann31insaf Respiratory Research Institute, Wiesbaden, Germany; 2University Of Manchester, Medicines Evaluation Unit, University Hospital of South Manchester, Manchester, UK; 3Novartis Pharma AG,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c28d4d07287f59790fdc29956058de63
https://www.dovepress.com/once-daily-nva237-improves-exercise-tolerance-from-the-first-dose-in-p-peer-reviewed-article-COPD
https://www.dovepress.com/once-daily-nva237-improves-exercise-tolerance-from-the-first-dose-in-p-peer-reviewed-article-COPD
Autor:
Tim Overend, Michael Looby, Didier Renard, Donald Banerji, Michael Gibbs, Helen Arievich, Vijay Alagappan
Publikováno v:
BMC Pulmonary Medicine
BMC Pulmonary Medicine, Vol 12, Iss 1, p 74 (2012)
BMC Pulmonary Medicine, Vol 12, Iss 1, p 74 (2012)
Background Glycopyrronium bromide (NVA237) is an inhaled long-acting muscarinic antagonist in development for treatment of COPD. This study compared the efficacy and safety of once-daily (OD) and twice-daily (BID) glycopyrronium bromide regimens, usi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98f528964dedcbf4a6318286fed596d8
https://pubmed.ncbi.nlm.nih.gov/23217058
https://pubmed.ncbi.nlm.nih.gov/23217058
This study assessed the cardiovascular safety of QVA149, an inhaled, once daily, bronchodilator combination containing two 24-hour bronchodilators, the long-acting β(2)-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium (NV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15a0f1f2e4cd6611ae5f884ee3d65ea7
https://hdl.handle.net/11380/647427
https://hdl.handle.net/11380/647427
Autor:
Cazzola, M, Matera, M
An important step in simplifying asthma and chronic obstructive pulmonary disease (COPD) management and improving adherence with prescribed therapy is to reduce the dose frequency to the minimum necessary to maintain disease control. Therefore, the i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::565a1a6609e4326941d4e2fbdfcd9f6d
https://europepmc.org/articles/PMC2567883/
https://europepmc.org/articles/PMC2567883/